'PARP'ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors.

Abstract

Fibrosis is a wound-healing process that results in tissue scarring and organ dysfunction. Several novel mechanisms of fibrogenesis have been discovered recently. In this review, we focus on the role of poly-ADP ribose polymerase (PARP) in major organ fibrosis, such as lungs, heart, liver, and kidneys. PARP is a dynamic enzyme that modulates different cellular proteins by the addition of PAR groups and mediates an array of cellular events in both normal physiological and pathophysiological states. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) recently approved several PARP inhibitors, such as olaparib, niraparib, talazoparib, and rucaparib, for the treatment of ovarian and germline BRCA-mutant breast cancers. Consequently, repurposing these drugs could provide an opportunity to counter organ fibrosis.

• Authors: Pooja Dhileepkumar Rao, Himanshu Sankrityayan, Anjali Srivastava, Yogesh A Kulkarni, Shrikant R Mulay, Anil Bhanudas Gaikwad
• Journal: Drug discovery today (Drug Discov Today) Vol. 25 Issue 7 Pg. 1253-1261 (07 2020) ISSN: 1878-5832 [Electronic] England
• PMID: 32371137 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2020 Elsevier Ltd. All rights reserved.

Chemical References

• Poly(ADP-ribose) Polymerase Inhibitors
• Poly(ADP-ribose) Polymerases

Topics

• Animals
• Breast Neoplasms (drug therapy, metabolism)
• Drug Repositioning (methods)
• Female
• Fibrosis (drug therapy, metabolism)
• Humans
• Ovarian Neoplasms (drug therapy, metabolism)
• Poly(ADP-ribose) Polymerase Inhibitors (pharmacology)
• Poly(ADP-ribose) Polymerases (metabolism)